Newsmakers In Medicine: Oncology Edition
March 11, 2010
Faculty | Activity Goal | Target Audience | CME Information | Disclosure

This independent CME activity is
supported by an educational grant from Genentech, Inc and OSI Oncology.

Chair

Roy S. Herbst, MD, PhD
Professor of Medicine
Department of Thoracic/Head
  and Neck Medical Oncology
University of Texas
  M.D. Anderson Cancer Center
Houston, Texas

Faculty

Julie R. Brahmer, MD
Assistant Professor of Oncology
The Sidney Kimmel
  Comprehensive Cancer Center
  at Johns Hopkins
Baltimore, Maryland

Ulrich Gatzemeier, MD
Head of the Department of
  Thoracic Oncology
Hospital Grosshansdorf
Grosshansdorf, Germany

John V. Heymach, MD
Assistant Professor, Thoracic/Head & Neck
  Medical Oncology
The University of Texas
  M.D. Anderson Cancer Center
Houston, Texas

Karen Kelly, MD
Professor of Medicine
University of Colorado Health
  Science Center
Aurora, Colorado

Rogerio Lilenbaum, MD
Clinical Assistant Professor
  of Medicine
University of Miami School
  of Medicine
Oncology/Hematology Associates
Mount Sinai Comprehensive
  Cancer Center
Miami Beach, Florida

Minesh P. Mehta, MD
Professor & Chair, Human
  Oncology
University of Wisconsin Medical
  School
Madison, Wisconsin

Ronald B. Natale, MD
Attending Physician
Cedars-Sinai Outpatient
  Cancer Center
at the Samuel Oschin
  Comprehensive Cancer Institute
Los Angeles, California

Alan B. Sandler, MD
Associate Professor of Medicine
Vanderbilt University Medical
  Center
Director, Thoracic Oncology
  Program
Director, Vanderbilt-Ingram Cancer Center
  Affiliate Network Program
Nashville, Tennessee

Mark A. Socinski, MD
Associate Professor of Medicine
Multi-Disciplinary Thoracic
  Oncology Program
Lineberger Comprehensive
  Cancer Center
University of North
  Carolina—Chapel Hill
Chapel Hill, North Carolina

CME INFORMATION-PHYSICIANS

Statement of Accreditation
Projects In Knowledge is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation
Projects In Knowledge designates this educational activity for a maximum of .25 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This activity is planned and implemented as an independent CME activity in accordance with the ACCME Essential Areas and Policies.

You can earn up to 1 credit for completing the entire 4-part series.

Activity Goal

The goal of this CME activity is to review state-of-the-science targeted treatment options, alone or in combination with conventional therapies, for patients with lung cancer.

Target Audience

This CME activity is designed for oncologists and other clinicians who treat patients with lung cancer.

Learning Objectives

Assess the impact of targeted therapies on lung cancer and improved patient outcomes, utilizing knowledge of the mechanism of action of these agents on cancer growth.

Formulate successful treatment strategies for patients with lung cancer based on an understanding of the mechanisms, efficacy, and safety of current and emerging targeted therapies.

Contract For Mutual Responsibility In CME

Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.

For more information on the contract, please click here.

Disclosure Information

The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Updated Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed.

For complete prescribing information on the products discussed during this CME activity, please see your current Physicians’ Desk Reference (PDR).

Projects In Knowledge's staff members have no significant relationships to disclose.

The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.

TECHNICAL REQUIREMENTS

Click here to view the technical requirements necessary for participation.

If you are experiencing any difficulty with this CME/CE activity, please contact us.

RELATED ITEMS

Editorial developed by
Projects In Knowledge, Inc.
Copyright © 2006-2010

Projects In Knowledge, Inc.
Overlook at Great Notch
150 Clove Road
Little Falls,
New Jersey 07424
Tel: (973) 890-8988
Fax: (973) 890-8866

New for 2007,
The Advanced Certificate Program: Lung Cancer Management
Current and emerging strategies for treating and managing patients with small-cell lung cancer (SCLC), non–small-cell lung cancer (NSCLC) and nonresectable lung cancers - learn more...

This CME activity has reached its termination date and no longer offers continuing education credit. Please note that expired CME activities may not contain the most up-to-date information available.

Click here to view our current activities in Oncology.

Part 1

Antiangiogenic Agents in Non–Small-Cell Lung Cancer


  Est. download time 56k: 10 min., Broadband: 2 min.

Listen to the first of 4 daily podcasts, which focuses on antiangiogenic agents in NSCLC.


Release Date: June 5, 2006.
Termination Date: June 5, 2007.
Estimated time for completion: 15 minutes.

Posted June 05, 2006.

Faculty Disclosures

Julie R. Brahmer, MD, has received grant/research support from Medarex Inc, Pfizer Inc, and Wyeth Pharmaceuticals; is on the speakers bureau of Sanofi-Aventis; and is a member of the advisory board of Genentech, Inc. Dr. Brahmer has disclosed that she will reference the unlabeled/unapproved use of bevacizumab in non–small-cell lung cancer.

Roy S. Herbst, MD, PhD, has received grant/research support from, is a consultant for, and is on the advisory board for AstraZeneca and Genentech, Inc.

John V. Heymach, MD, is a consultant for, is on the advisory boards of, and has received honoraria from AstraZeneca LP and Genentech, Inc. Dr. Heymach has disclosed that he will reference the unlabeled/unapproved use of ZD6474.

Alan B. Sandler, MD, has received grant/research support from Sanofi-Aventis and Genentech, Inc; and is a consultant for Genentech, Inc. Dr. Sandler has disclosed that he will reference the unlabeled/unapproved use of bevacizumab in non–small-cell lung cancer.



Top

Part 2

Treating NSCLC by Inhibiting Multiple Molecular Targets


  Est. download time 56k: 10 min., Broadband: 2 min.

Listen to the second of 4 daily podcasts, which focuses on treating NSCLC by inhibiting multiple molecular targets.

Release Date: June 6, 2006.
Termination Date: June 6, 2007.
Estimated time for completion: 15 minutes.

Posted June 06, 2006.

Faculty Disclosures

Ulrich Gatzemeier, MD, is a consultant for Eli Lilly and Company and Roche Pharmaceuticals; and is on the advisory board of AstraZeneca LP, Eli Lilly and Company, and Roche Pharmaceuticals. Dr. Gatzemeier will be referencing the unlabeled/unapproved use of sorafenib.

Roy S. Herbst, MD, PhD, has received grant/research support from, is a consultant for, and is on the advisory board for AstraZeneca and Genentech, Inc.

Mark A. Socinski, MD, has received grant/research support from Abraxis Oncology, Amgen Inc, AstraZeneca LP, Eli Lilly and Company, Genentech, Inc, Pfizer Inc, and Sanofi-Aventis; and is on the speakers bureau of Abraxis Oncology, Eli Lilly and Company, Genentech, Inc, and Sanofi-Aventis. Dr. Socinski will be referencing the unlabeled/unapproved use of sunitinib malate in lung cancer.



Top

Part 3

Dealing with Brain Metastases in NSCLC Patients and Other Issues


  Est. download time 56k: 10 min., Broadband: 2 min.

Listen to the third of 4 daily podcasts, which focuses on the slowing progression of neurologic symptoms following brain metastasis, the benefits of targeting angiogenesis in patients refractory to platinum-based chemotherapy, and first-line therapy in patients with poor performance status.

Release Date: June 7, 2006.
Termination Date: June 7, 2007.
Estimated time for completion: 15 minutes.

Posted June 07, 2006.

Faculty Disclosures

Rogerio Lilenbaum, MD, is a consultant for Genentech, Inc. Dr. Lilenbaum will not be referencing any unlabeled/unapproved uses of drugs or products.

Minesh P. Mehta, MD, has received grant/research support from Pharmacyclics, Inc. Dr. Mehta will be referencing the unlabeled/unapproved uses of motexafin gadolinium in lung cancer.

Robert B. Natale, MD, has received grant/research support from Amgen Inc, AstraZeneca Pharmaceuticals LP, Eli Lilly and Company, Pfizer Inc, Millennium, and Pharmacyclics, Inc; is on the advisory boards of Amgen Inc, AstraZeneca Pharmaceuticals LP, Eli Lilly and Company, and Pharmacyclics, Inc; and has received honoraria from Eli Lilly and Company. Dr. Natale will be referencing the unlabeled/unapproved use of ZD6474.



Top

Part 4

Response Predictors and Sequencing of Targeted Therapy


  Est. download time 56k: 10 min., Broadband: 2 min.

I invite you to listen to the fourth and final daily podcast, which focuses on the identification of markers predicting response to targeted therapy and the relative benefits of concurrent versus sequential administration of EGFR targeted antibodies and chemotherapy in NSCLC patients.

 

Release Date: June 8, 2006.
Termination Date: June 8, 2007.
Estimated time for completion: 15 minutes.

Closing comments from Dr. Roy Herbst

Posted June 08, 2006.

Faculty Disclosures

Roy S. Herbst, MD, PhD, has received grant/research support from, is a consultant for, and is on the advisory board for AstraZeneca and Genentech, Inc.

Karen Kelly, MD, is on the advisory boards of Bristol-Myers Squibb Company and Imclone. Dr. Kelly will be referencing the unlabeled/unapproved use of cetuximab in lung cancer.



Top

RECENT POSTS

About this Activity

Daily Podcasts: News and Views on NSCLC from the 2006 ASCO Annual Meeting is a series of lively 15-minute interviews conducted with top oncology experts who provide their insights on the latest scientific advances in treating lung cancer and discuss highlights of some of the presentations and poster sessions from the meeting.

These podcasts, posted daily from June 5 to June 8, 2006, are available as streaming audio or can be downloaded to a computer or MP3 player.


Estimated time for completion of this activity: 1 hour (15 minutes for each posting)